MEDICAL DIAGNOSTIC TESTS INFECTIOUS

Brand Owner Address Description
XFREE BioGX, Inc. 1500 1st Ave N Birmingham AL 35203 Medical diagnostic tests for infectious and genetic diseases; medical diagnostic tests including reagents to test for infectious and genetic diseases; medical diagnostic tests employing polymerase chain reaction (PCR) to test for infectious and genetic diseases; reagents, namely, reagents for medical diagnostic testing use; molecular reagents, namely, lyophilized reagents for chemical testing purposes for medical or veterinary use; molecular reagents, namely, custom lyophilized reagents for chemical testing purposes for medical or veterinary use; molecular reagents, namely, lyophilized reagents for chemical testing purposes, namely, clinical medical reagents and chemical reagents for medicinal pharmaceutical use; molecular reagents, namely, molecular reagents for medical diagnostic use in connection with genetic materials; molecular reagents, namely, molecular reagents for medical diagnostic use in real-time PCR and nucleic sequencing platforms;X FREE;Reagents, namely, reagents for medical research testing or for scientific research use; molecular reagents, namely, lyophilized reagents for chemical testing purposes in scientific research; molecular reagents, namely, custom lyophilized reagents for chemical testing for scientific or medical research purposes; molecular reagents, namely, lyophilized reagents for chemical testing purposes, namely, for clinical laboratory use, food safety testing, pharmaceutical testing and water quality analysis for scientific research purposes; molecular reagents, namely, molecular diagnostic reagents for scientific or research use in connection with genetic materials; molecular reagents, namely, molecular reagents for use in real-time PCR and nucleic sequencing platforms for scientific or medical research use;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Appropriate determinations in a series of tests, which transition from more passive tests to more active tests, control the admission of data streams onto a network data path. More passive tests can include promiscuous mode and packet-pair tests. When the results of more passive tests indicate a reduce likelihood of a data stream causing a network data path to transition into a congested state, the network data path can be actively probed to make a more precise determination on the likelihood of congestion. A train of diagnostic data packets is transmitted at a diagnostic data transfer rate having a significantly reduced chance of causing congestion. A train of target data packets is transmitted at a requested application transfer data rate. The number of target data packets received within a specified delay threshold is compared to the number of diagnostic data packets receive with the delay threshold.